<DOC>
	<DOCNO>NCT00944450</DOCNO>
	<brief_summary>This study establish MK0431 100 mg anhydrous formulation tablet bioequivalent MK0431 100 mg monohydrate final market image ( FMI ) tablet .</brief_summary>
	<brief_title>Study Bioequivalence Two Tablet Forms MK0431 ( 0431-027 )</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>Subject good health Female subject must negative pregnancy test Subject within 30 % ideal body weight Subject smoke Subject agree follow study guideline Subject history illness might confound result study make participation unsafe subject Subject history hypoglycemia Subject history hepatic disease Subject take oral , parenteral , topical implantable contraceptive</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>